Peter H. O’Donnell

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists

  Clinical Genitourinary Cancer · 2025-12-20

• Association of <scp> <i>SULT2A1</i> </scp> Locus With Abiraterone Clearance in the Alliance <scp>A031201</scp> : Randomized Phase <scp>III</scp> Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer

  Clinical and Translational Science · 2025-12-01

• LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study

  Annals of Oncology · 2025-09-01 · 34 citations

• 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y

  Annals of Oncology · 2025-09-01 · 1 citations

• Results of the <scp>ACCOuNT</scp> Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

  Clinical Pharmacology & Therapeutics · 2025-08-22 · 1 citations

• HER2 and urothelial carcinoma: current understanding and future directions

  Nature Reviews Urology · 2025-08-15 · 17 citations

• Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

  Clinical Pharmacology & Therapeutics · 2025-06-27

• Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results.

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey.

  Journal of Clinical Oncology · 2025-05-28

• Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study

  Supportive Care in Cancer · 2025-04-08

• Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing

  Clinical and Translational Science · 2025-04-01 · 2 citations

• A National Study Among Diverse US Populations of Exposure to Prescription Medications with Evidence‐Based Pharmacogenomic Information

  Clinical Pharmacology & Therapeutics · 2025-03-03 · 4 citations

• NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors.

  Journal of Clinical Oncology · 2025-02-10 · 3 citations

• Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin/pembrolizumab (EVP) in the evolving landscape of locally advanced/metastatic (la/m) urothelial cancer (UC).

  Journal of Clinical Oncology · 2025-02-10 · 4 citations

• Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

  ESMO Open · 2024-12-01 · 28 citations

• Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative Care

  Journal of Pain Research · 2024-12-01 · 2 citations

• Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma

  Clinical and Translational Radiation Oncology · 2024-10-29 · 1 citations

• Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011

  Cancer · 2024-10-28 · 2 citations

• Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer

  Journal of Oncology Pharmacy Practice · 2024-10-13

• 165 (PB153): NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)

  European Journal of Cancer · 2024-10-01